{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:58:11Z","timestamp":1790956691840,"version":"4.1.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Overdose is the leading cause of maternal mortality in the US, yet evidence on how medications for opioid use disorder (MOUD) affect postpartum overdose and mortality risk is limited. It is unclear whether cumulative MOUD exposure during this period reduces overdose or death beyond 90 days post partum.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine whether longer duration of MOUD dispensed during pregnancy and early post partum is associated with reduced overdose or death through 365 days post partum.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This is a retrospective cohort study of individuals delivering between 2007 and 2020, assessed through 1 year post partum or until the first outcome, through 2021. The study used Tennessee Medicaid (TennCare) data linked to vital records (birth and death certificates) and Tennessee Hospital Discharge Data. Participants were individuals aged 15 to 44 years with at least 1 day of dispensed MOUD during the exposure window (90 days before to 41 days after delivery), a delivery at least 20 weeks\u2019 gestation, and continuous TennCare enrollment during the exposure period. Data were analyzed from July 2024 to July 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Total unique, nonoverlapping days of dispensed MOUD (buprenorphine and\/or naltrexone) from 90 days before delivery through 41 days after delivery, with overlapping fills deduplicated so each calendar day was counted only once.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the first occurrence of all-cause death or overdose (opioid or nonopioid) from inpatient, outpatient, and emergency department claims 42 to 365 days post partum. Multivariable Cox proportional hazards models were used to estimate the association between MOUD days\u2019 supply and risk of death or overdose, adjusting for maternal and clinical characteristics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The cohort included 9360 pregnancies among 7776 individuals (median [IQR] age at delivery, 27 [24-31] years). The 1-year postpartum risk of death or overdose was 1.58% (148 individuals), with a median (IQR) time to event of 186.5 (92.5-258.8) days. The median (IQR) MOUD duration during the 132-day exposure period was 88 (43-111) days. Longer MOUD duration was associated with lower risk of death or overdose, with the lowest hazard at 132 days\u2019 supply (adjusted hazard ratio for 132 vs 1 day, 0.52; 95% CI, 0.31-0.88).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Longer duration of MOUD receipt during pregnancy and early post partum was associated with lower risk of overdose or death in the first year post partum, underscoring the importance of supporting continuous MOUD treatment during this period.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.37214","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:21Z","timestamp":1790955021000},"page":"e2637214","source":"Crossref","is-referenced-by-count":0,"title":["Duration of Medication Use for Opioid Use Disorder and Risk of Postpartum Overdose and Death"],"prefix":"10.1001","volume":"9","author":[{"given":"Ahra","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Wiese","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Osmundson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"You","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G.","family":"Grijalva","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"},{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Adgent","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra C.","family":"Sundermann","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Spieker","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Patrick","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia"},{"name":"Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, Georgia"},{"name":"Health Services Research Center, Emory University School of Medicine, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Leech","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"7","key":"zoi261003r1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMc2512078","article-title":"Overdose, homicide, and suicide as causes of maternal death in the United States.","volume":"394","author":"Azad","year":"2026","journal-title":"N Engl J Med"},{"issue":"31","key":"zoi261003r2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization\u2014United States, 1999-2014.","volume":"67","author":"Haight","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi261003r3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2020.24991","article-title":"Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017.","volume":"325","author":"Hirai","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"zoi261003r4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1753495X20971163","article-title":"Opioid use in pregnancy: an emerging health crisis.","volume":"14","author":"Zipursky","year":"2021","journal-title":"Obstet Med"},{"issue":"1","key":"zoi261003r6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/AOG.0000000000001446","article-title":"Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic.","volume":"128","author":"Krans","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"4.11","key":"zoi261003r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.1814","article-title":"Buprenorphine treatment in pregnancy and maternal-infant outcomes.","volume":"6","author":"Krishnapura","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"11","key":"zoi261003r10","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1001\/jamapediatrics.2025.3067","article-title":"Cost-effectiveness of treatment for opioid use disorder in pregnancy and its impact on birth outcomes.","volume":"179","author":"Leech","year":"2025","journal-title":"JAMA Pediatr"},{"issue":"12","key":"zoi261003r11","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1111\/add.15582","article-title":"Outcomes associated with the use of medications for opioid use disorder during pregnancy.","volume":"116","author":"Krans","year":"2021","journal-title":"Addiction"},{"issue":"1","key":"zoi261003r12","doi-asserted-by":"publisher","first-page":"59.e1","DOI":"10.1016\/j.ajog.2024.12.001","article-title":"Association between buprenorphine dose and outcomes among pregnant persons with opioid use disorder.","volume":"233","author":"Jarlenski","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"zoi261003r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7964","article-title":"Association of duration of methadone or buprenorphine use during pregnancy with risk of nonfatal drug overdose among pregnant persons with opioid use disorder in the US.","volume":"5","author":"Jarlenski","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi261003r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13456","article-title":"Association of pregnancy and insurance status with treatment access for opioid use disorder.","volume":"3","author":"Patrick","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi261003r15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1001\/jamainternmed.2023.2826","article-title":"Buprenorphine out-of-pocket costs and discontinuation in privately insured adults with opioid use disorder.","volume":"183","author":"Leech","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi261003r16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid.","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi261003r17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/AOG.0000000000004649","article-title":"Pregnancy-associated deaths due to drugs, suicide, and homicide in the United States, 2010-2019.","volume":"139","author":"Margerison","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi261003r18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/pharmacy11050131","article-title":"Methadone treatment gap in Tennessee and how medication units could bridge the gap: a review.","volume":"11","author":"Risby","year":"2023","journal-title":"Pharmacy (Basel)"},{"key":"zoi261003r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108236","article-title":"Substance use disorders and risk of severe maternal morbidity in the United States.","volume":"216","author":"Jarlenski","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi261003r22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/ADM.0000000000000780","article-title":"Healthcare patterns of pregnant women and children affected by OUD in 9 state Medicaid populations.","volume":"15","author":"Jarlenski","year":"2021","journal-title":"J Addict Med"},{"issue":"1","key":"zoi261003r24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40290-020-00371-8","article-title":"Building a data linkage foundation for mother-child pharmacoepidemiology research.","volume":"35","author":"Whitmore","year":"2021","journal-title":"Pharmaceut Med"},{"issue":"2","key":"zoi261003r27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/AOG.0000000000002734","article-title":"Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts.","volume":"132","author":"Schiff","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"2","key":"zoi261003r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59342","article-title":"Pregnancy-associated mortality due to homicide, suicide, and drug overdose.","volume":"8","author":"Wallace","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi261003r30","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70139","article-title":"Agreement between parental self-reported antiseizure medication use and dispensed prescription records from a national prescription database.","volume":"34","author":"Olstad","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"zoi261003r31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/pds.4264","article-title":"The concordance between self-reported medication use and pharmacy records in pregnant women.","volume":"26","author":"Cheung","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"zoi261003r32","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/bcp.15609","article-title":"Adherence to prescription medication during pregnancy: do pregnant women use pharmacological treatment as prescribed?","volume":"89","author":"de Korte","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"zoi261003r33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/AOG.0000000000004223","article-title":"Severe maternal morbidity and risk of mortality beyond the postpartum period.","volume":"137","author":"Ukah","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi261003r34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/AOG.0b013e31826d60c5","article-title":"Severe maternal morbidity among delivery and postpartum hospitalizations in the United States.","volume":"120","author":"Callaghan","year":"2012","journal-title":"Obstet Gynecol"},{"key":"zoi261003r8","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019"},{"key":"zoi261003r5","unstructured":"Centers for Disease Control and Prevention. Opioid use during pregnancy. May 7, 2025. Accessed August 31, 2026. https:\/\/www.cdc.gov\/opioid-use-during-pregnancy\/about\/index.html"},{"key":"zoi261003r9","unstructured":"Substance Abuse and Mental Health Services Administration. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants: HHS publication 18-5054. 2018. Accessed August 31, 2026. https:\/\/library.samhsa.gov\/sites\/default\/files\/sma18-5054.pdf"},{"key":"zoi261003r19","unstructured":"Tennessee Department of Health, Division of Family Health & Wellness. Maternal mortality in Tennessee: annual report 2025. December 10, 2025. Accessed August 31, 2026. https:\/\/www.tn.gov\/content\/dam\/tn\/health\/2025-notcom\/Maternal%20Mortality%20Review%20Report%202025.pdf"},{"key":"zoi261003r20","unstructured":"Kaiser Family Foundation. Births financed by Medicaid by metropolitan status. Accessed August 31, 2026. https:\/\/www.kff.org\/medicaid\/state-indicator\/births-financed-by-medicaid\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D"},{"key":"zoi261003r23","unstructured":"Tennessee Department of Health. Neonatal abstinence syndrome in Tennessee 2022: 2024 NAS surveillance annual report. July 2024. Accessed August 31, 2026. https:\/\/www.tn.gov\/content\/dam\/tn\/health\/program-areas\/NAS-Annual-Report.pdf"},{"key":"zoi261003r25","doi-asserted-by":"crossref","unstructured":"Hoyert? DL. Maternal mortality rates in the United States, 2024. Centers for Disease Control and Prevention. March 4, 2026. Accessed August 31, 2026. https:\/\/stacks.cdc.gov\/view\/cdc\/174651","DOI":"10.15620\/cdc\/174651"},{"key":"zoi261003r26","unstructured":"Centers for Disease Control and Prevention. Identifying severe maternal morbidity (SMM). May 15, 2024. Accessed August 31, 2026. https:\/\/www.cdc.gov\/maternal-infant-health\/php\/severe-maternal-morbidity\/icd.html"},{"key":"zoi261003r29","unstructured":"Centers for Disease Control and Prevention. Circumstances contributing to pregnancy-related deaths: data from maternal mortality review committees in 38 U.S. States, 2020. April 20, 2026. Accessed August 31, 2026. https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/maternal-mortality\/php\/report\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854761\/kim_2026_oi_261003_1790346346.40337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:23Z","timestamp":1790955023000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.37214","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}